Comparing demographic and clinical characteristics of dengue patients with and without IFN-I NAbs
| | Overall | NAb(+) | DSS NAb(−) | DHF NAb(−) | DF NAb(−) | P (NAb(+) group compared with the other groups) |
|---|---|---|---|---|---|---|
| Demographic | ||||||
| N | 216 | 7 | 6 | 36 | 167 | |
| Age (median [IQR]) | 50.75 [32.97–61.61] | 75.34 [54.16–81.90] | 70.50 [59.71–80.53] | 61.36 [51.04–69.39] | 46.97 [29.58–57.26] | 1.000/1.000/0.007 |
| 0–49 (%) | 103 (47.7) | 1 (14.3) | 1 (16.7) | 7 (19.4) | 94 (56.3) | |
| 50–59 (%) | 49 (22.7) | 2 (28.6) | 1 (16.7) | 8 (22.2) | 38 (22.8) | |
| 60–69 (%) | 36 (16.7) | 0 | 1 (16.7) | 12 (33.3) | 23 (13.8) | |
| 70–79 (%) | 21 (9.7) | 2 (28.6) | 1 (16.7) | 8 (22.2) | 10 (6.0) | |
| 80+ (%) | 7 (3.2) | 2 (28.6) | 2 (33.3) | 1 (2.8) | 2 (1.2) | |
| Sex (male [%]) | 123 (56.9) | 3 (42.9) | 4 (66.7) | 14 (38.9) | 102 (61.1) | 0.592/1.000/0.437 |
| Secondary dengue infection (%) | 3 (1.4) | 1 (14.3) | 1 (16.7) | 1 (2.8) | 0 | 1.000/0.302/0.040 |
| Comorbidities | ||||||
| Hypertension (%) | 34 (15.7) | 3 (42.9) | 1 (16.7) | 7 (19.4) | 23 (13.8) | 0.559/0.325/0.069 |
| Diabetes (%) | 20 (9.3) | 2 (28.6) | 0 | 17 (47.2) | 11 (6.6) | 0.462/0.437/0.088 |
| Heart disease (%) | 12 (5.6) | 2 (28.6) | 0 | 3 (8.3) | 7 (4.2) | 0.462/0.180/0.044 |
| Renal disease (%) | 12 (5.6) | 0 | 1 (16.7) | 6 (16.7) | 5 (3.0) | 1.000/0.567/1.000 |
| Malignant tumor (%) | 5 (2.3) | 0 | 0 | 4 (11.1) | 1 (0.6) | 1.000/1.000/1.000 |
| Neuropsychopathy (%) | 4 (1.9) | 0 | 0 | 3 (8.3) | 1 (0.6) | 1.000/1.000/1.000 |
| Complication | ||||||
| Hypoproteinemia (%) | 67 (31.0) | 7 (100) | 6 (100) | 33 (91.7) | 21 (12.6) | 1.000/1.000/<0.001 |
| Shock (%) | 5 (2.3) | 1 (14.3) | 4 (66.7) | 0 | 0 | 0.266/0.163/0.040 |
| Hepatic injury (%) | 126 (58.3) | 5 (71.4) | 5 (83.3) | 24 (66.7) | 92 (55.1) | 1.000/1.000/0.466 |
| Kidney injury (%) | 21 (9.7) | 3 (42.9) | 5 (83.3) | 6 (16.7) | 7 (4.2) | 0.592/0.147/0.004 |
| Cardiac injury (%) | 52 (24.1) | 7 (100) | 4 (66.7) | 8 (22.2) | 33 (19.8) | 1.000/<0.001/<0.001 |
| Cerebral injury (%) | 17 (7.9) | 0 | 3 (50.0) | 6 (16.7) | 8 (4.8) | 0.192/0.567/1.000 |
| Treatment | ||||||
| Rehydration (%) | 203 (94.0) | 7 (100) | 6 (100) | 34 (94.4) | 156 (93.4) | 1.000/1.000/1.000 |
| Glucocorticoids (%) | 13 (6.0) | 1 (14.3) | 2 (33.3) | 5 (13.9) | 5 (3.0) | 0.443/1.000/0.221 |
| Platelet transfusion (%) | 32 (14.8) | 6 (85.7) | 3 (50.0) | 9 (25.0) | 14 (8.4) | 0.266/0.005/<0.001 |
| ALB infusion (%) | 18 (8.3) | 3 (42.6) | 6 (100) | 7 (19.4) | 2 (1.2) | 0.266/0.325/<0.001 |
| Days of hospitalization (median [IQR]) | 5.89 [4.66–7.78] | 6.00 [5.41–6.93] | 11.00 [7.17–26.00] | 7.18 [5.30–9.99] | 5.78 [4.54–7.37] | 0.412/1.000/1.000 |
| | Overall | NAb(+) | DSS NAb(−) | DHF NAb(−) | DF NAb(−) | P (NAb(+) group compared with the other groups) |
|---|---|---|---|---|---|---|
| 216 | 7 | 6 | 36 | 167 | | |
| Age (median [IQR]) | 50.75 [32.97–61.61] | 75.34 [54.16–81.90] | 70.50 [59.71–80.53] | 61.36 [51.04–69.39] | 46.97 [29.58–57.26] | 1.000/1.000/0.007 |
| 0–49 (%) | 103 (47.7) | 1 (14.3) | 1 (16.7) | 7 (19.4) | 94 (56.3) | |
| 50–59 (%) | 49 (22.7) | 2 (28.6) | 1 (16.7) | 8 (22.2) | 38 (22.8) | |
| 60–69 (%) | 36 (16.7) | 0 | 1 (16.7) | 12 (33.3) | 23 (13.8) | |
| 70–79 (%) | 21 (9.7) | 2 (28.6) | 1 (16.7) | 8 (22.2) | 10 (6.0) | |
| 80+ (%) | 7 (3.2) | 2 (28.6) | 2 (33.3) | 1 (2.8) | 2 (1.2) | |
| Sex (male [%]) | 123 (56.9) | 3 (42.9) | 4 (66.7) | 14 (38.9) | 102 (61.1) | 0.592/1.000/0.437 |
| Secondary dengue infection (%) | 3 (1.4) | 1 (14.3) | 1 (16.7) | 1 (2.8) | 0 | 1.000/0.302/0.040 |
| Hypertension (%) | 34 (15.7) | 3 (42.9) | 1 (16.7) | 7 (19.4) | 23 (13.8) | 0.559/0.325/0.069 |
| Diabetes (%) | 20 (9.3) | 2 (28.6) | 0 | 17 (47.2) | 11 (6.6) | 0.462/0.437/0.088 |
| Heart disease (%) | 12 (5.6) | 2 (28.6) | 0 | 3 (8.3) | 7 (4.2) | 0.462/0.180/0.044 |
| Renal disease (%) | 12 (5.6) | 0 | 1 (16.7) | 6 (16.7) | 5 (3.0) | 1.000/0.567/1.000 |
| Malignant tumor (%) | 5 (2.3) | 0 | 0 | 4 (11.1) | 1 (0.6) | 1.000/1.000/1.000 |
| Neuropsychopathy (%) | 4 (1.9) | 0 | 0 | 3 (8.3) | 1 (0.6) | 1.000/1.000/1.000 |
| Hypoproteinemia (%) | 67 (31.0) | 7 (100) | 6 (100) | 33 (91.7) | 21 (12.6) | 1.000/1.000/<0.001 |
| Shock (%) | 5 (2.3) | 1 (14.3) | 4 (66.7) | 0 | 0 | 0.266/0.163/0.040 |
| Hepatic injury (%) | 126 (58.3) | 5 (71.4) | 5 (83.3) | 24 (66.7) | 92 (55.1) | 1.000/1.000/0.466 |
| Kidney injury (%) | 21 (9.7) | 3 (42.9) | 5 (83.3) | 6 (16.7) | 7 (4.2) | 0.592/0.147/0.004 |
| Cardiac injury (%) | 52 (24.1) | 7 (100) | 4 (66.7) | 8 (22.2) | 33 (19.8) | 1.000/<0.001/<0.001 |
| Cerebral injury (%) | 17 (7.9) | 0 | 3 (50.0) | 6 (16.7) | 8 (4.8) | 0.192/0.567/1.000 |
| Rehydration (%) | 203 (94.0) | 7 (100) | 6 (100) | 34 (94.4) | 156 (93.4) | 1.000/1.000/1.000 |
| Glucocorticoids (%) | 13 (6.0) | 1 (14.3) | 2 (33.3) | 5 (13.9) | 5 (3.0) | 0.443/1.000/0.221 |
| Platelet transfusion (%) | 32 (14.8) | 6 (85.7) | 3 (50.0) | 9 (25.0) | 14 (8.4) | 0.266/0.005/<0.001 |
| ALB infusion (%) | 18 (8.3) | 3 (42.6) | 6 (100) | 7 (19.4) | 2 (1.2) | 0.266/0.325/<0.001 |
| Days of hospitalization (median [IQR]) | 5.89 [4.66–7.78] | 6.00 [5.41–6.93] | 11.00 [7.17–26.00] | 7.18 [5.30–9.99] | 5.78 [4.54–7.37] | 0.412/1.000/1.000 |
Data are reported as N, N (%), or median [IQR]. Fisher’s exact test was used to analyze the effect of dichotomous variables, and a Kruskal–Wallis test was used for continuous variables. A P value <0.05 was considered to indicate statistical significance. IQR, interquartile range.
Sharing content requires targeting cookies to be enabled. Please update your cookie preferences to use this feature.